RenovoRx shares surge 11.93% premarket as CEO highlights commercial progress and Phase III trial updates at AGP showcase.

RenovoRx surged 11.93% in premarket trading following the announcement that CEO Shaun Bagai will present at the AGP Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20. The presentation highlights year-to-date revenue of $900,000 through September 30, 2025, growing adoption of RenovoCath as a standalone device, and advancements in the Phase III TIGeR-PaC trial for intra-arterial gemcitabine in pancreatic cancer. These updates underscore commercial traction and clinical progress, reinforcing investor confidence in the company’s revenue potential and therapeutic pipeline. The event also emphasizes capital-efficient studies and real-world data collection, which could accelerate regulatory validation and broader market adoption of RenovoCath. The positive sentiment aligns with the premarket rally, driven by tangible milestones in commercialization and clinical development.